message_id,index,text,greet,target_group,mood_unhappy,thanks,out_of_scope,tell_name,deny,mood_great,age,stop,item_number,site_id,site_name,sub_list,CRA_mobile,requested_slot,version,main,entity_values,non_answer,token,sender_name,sender_id,index_list,csp_item,qa_item,sub,sub_entity,sub_confidence_entity,sub_value,sub_extractor,sub_processors,action,user_time,bot_text,bot_time,inform_protocol,new_scope,affirm,bot_challenge,goodbye,treatment_history,nlu_fallback,clean_text
9d63f06086094be4835385b9c88114f5,confidence,hello,0.9993460774421692,0.00019424830679781735,0.0001380418543703854,8.274911670014262e-05,4.656507371691987e-05,4.244855517754331e-05,3.908176222466864e-05,3.8918635254958645e-05,3.8266651245066896e-05,3.359946276759729e-05,,1111111111,北京肿瘤医院,,11111111111,,2.0,,,,,zhao,123465,,,,,,,,,,,2022-06-28 22:23:59.326709,"您好zhaoyisheng，北京肿瘤医院的方案版本是2.0。您可以直接问具体的问题，也可以按照小易的说明逐步问。同时，也可以点击选项卡提问。
<b>小易推荐如下选项，请参照选择。谢谢</b>",2022-06-28 22:23:59.509425,,,,,,,,hello
f319a5ababf74ffb81ae733604c4b794,confidence,"/inform_protocol{""sub"": ""突变""}",,,,,,,,,,,,1111111111,北京肿瘤医院,,,,2.0,入选标准,,,,zhao,123465,,排除标准第2条,,,sub,0,突变,0,0,0,2022-06-28 22:24:02.622411,"试验方案第68页 
排除标准第2条 
携带靶向EGFR改变（或其他靶向突变，包括但不限于ALK，如果通过常规检测确定为有获批可用治疗的靶向改变）的肿瘤。	/DL04 V2
<b>此项下还有以下Q＆A Log中问题，请参照选择。您也可以输入其他问题。谢谢</b>",2022-06-28 22:24:07.249685,1.0,,,,,,,突变
52682c05dcae43ce9cecb1813a53ba48,confidence,soa,,0.0002577763225417584,,0.0002118445554515347,0.00015689997235313058,,0.0006092384574003518,0.0005043703131377697,,0.00020249794761184603,,1111111111,北京肿瘤医院,,,,2.0,,,<104>,,zhao,123465,,,,,,,,,,,2022-06-28 22:24:12.389871,"zhaoyisheng老师，您的问题""soa"",现在小易还不能回答，我会转给负责咱们中心的CRA。<104>",2022-06-28 22:24:12.482866,,0.996529757976532,0.0011614724062383175,0.00023625149333383888,0.00012988958042114973,,,soa
034dbe3b719a4a8e9ade57d75b6771c4,confidence,腹水,7.081615131376712e-27,,7.343545455673264e-27,,,1.6990496191485863e-27,,2.6918796018038282e-27,,4.1253627409208586e-27,,1111111111,北京肿瘤医院,,,,2.0,入选标准,,,,zhao,123465,,排除标准第6条,,,sub,0.0,腹水,RegexEntityExtractor,0,0,2022-06-28 22:24:17.825417,"试验方案第69页 
排除标准第6条 
需要引流、腹腔分流术或浓缩无细胞腹水再输注疗法治疗的胸腔积液、腹水或心包积液	/DL04 V2
<b>此项下还有以下Q＆A Log中问题，请参照选择。您也可以输入其他问题。谢谢</b>",2022-06-28 22:24:18.225176,1.0,1.7640988659852374e-27,1.6310082475503352e-27,,,4.530236741247799e-27,2.275653014826703e-27,腹水
034dbe3b719a4a8e9ade57d75b6771c4,confidence,腹水,7.081615131376712e-27,,7.343545455673264e-27,,,1.6990496191485863e-27,,2.6918796018038282e-27,,4.1253627409208586e-27,,1111111111,北京肿瘤医院,,,,2.0,入选标准,,,,zhao,123465,,排除标准第6条,,,sub,0.9998589754104614,腹水,DIETClassifier,0,0,2022-06-28 22:24:17.825417,"试验方案第69页 
排除标准第6条 
需要引流、腹腔分流术或浓缩无细胞腹水再输注疗法治疗的胸腔积液、腹水或心包积液	/DL04 V2
<b>此项下还有以下Q＆A Log中问题，请参照选择。您也可以输入其他问题。谢谢</b>",2022-06-28 22:24:18.225176,1.0,1.7640988659852374e-27,1.6310082475503352e-27,,,4.530236741247799e-27,2.275653014826703e-27,腹水
034dbe3b719a4a8e9ade57d75b6771c4,confidence,腹水,7.081615131376712e-27,,7.343545455673264e-27,,,1.6990496191485863e-27,,2.6918796018038282e-27,,4.1253627409208586e-27,,1111111111,北京肿瘤医院,,,,2.0,入选标准,,,,zhao,123465,,排除标准第6条,,,sub,0.0,腹水,RegexEntityExtractor,0,0,2022-06-28 22:24:17.825417,"试验方案第69页 
排除标准第6条 
需要引流、腹腔分流术或浓缩无细胞腹水再输注疗法治疗的胸腔积液、腹水或心包积液	/DL04 V2
<b>此项下还有以下Q＆A Log中问题，请参照选择。您也可以输入其他问题。谢谢</b>",2022-06-28 22:24:18.225176,1.0,1.7640988659852374e-27,1.6310082475503352e-27,,,4.530236741247799e-27,2.275653014826703e-27,腹水
e06f248aecec48d38aa651064dc0e338,confidence,"/inform_protocol{""sub"": ""胸腔积液,洗脱期,穿刺""}",,,,,,,,,,,,1111111111,北京肿瘤医院,,,,2.0,入选标准,,,,zhao,123465,,排除标准第6条,Q&A,,sub,0,"胸腔积液,洗脱期,穿刺",0,0,0,2022-06-28 22:24:23.361028,"<b>排除标准第6条问题: </b>反复胸腔穿刺的患者被排除在外吗？
<b>
排除标准第6条回答: </b>只要符合表9中的洗脱期要求，这并不排除以前做过任何数量胸腔积液引流或胸腔穿刺术的患者。根据表9，胸腔积液引流至少需要2周的洗脱期。

<b>此项下还有以下Q＆A Log中问题，请参照选择。您也可以输入其他问题。谢谢</b>",2022-06-28 22:24:23.742796,1.0,,,,,,,"胸腔积液,洗脱期,穿刺"
832fcc467d21445990106a129e99a9ea,confidence,hello,0.9993460774421692,0.00019424830679781735,0.0001380418543703854,8.274911670014262e-05,4.656507371691987e-05,4.244855517754331e-05,3.908176222466864e-05,3.8918635254958645e-05,3.8266651245066896e-05,3.359946276759729e-05,,1111111111,北京肿瘤医院,,11111111111,,2.0,,,,,zhao,123465,,,,,,,,,,,2022-06-28 22:27:57.355449,"您好zhaoyisheng，北京肿瘤医院的方案版本是2.0。您可以直接问具体的问题，也可以按照小易的说明逐步问。同时，也可以点击选项卡提问。
<b>小易推荐如下选项，请参照选择。谢谢</b>",2022-06-28 22:27:57.578194,,,,,,,,hello
018b9375f1ba4dd4a38b48dc2f9dc656,confidence,cns,2.589686631244412e-25,,7.2082766721010185e-25,,,8.25692019698924e-26,,2.0226592057688212e-25,,3.114061703429383e-25,,1111111111,北京肿瘤医院,,,,2.0,入选标准,,,,zhao,123465,,排除标准第4条,,,sub,0.9997705817222595,CNS转移,DIETClassifier,['EntitySynonymMapper'],0,2022-06-28 22:28:01.392512,"试验方案第68页 
排除标准第4条 
任何脊髓压迫、软脑膜疾病或临床活动性CNS转移。注：临床活动性 CNS转移定义为未经治疗且有症状的、或需要皮质类固醇或抗惊厥药治疗以控制相关症状。
CNS 转移受试者必须既往完成过局部治疗。
−  如果无症状或神经系统稳定且已从既往治疗的急性毒性作用中恢复，则允许既往接受过治疗的 CNS 转移受试者入组。
− 接受放疗的 CNS 转移受试者必须符合以下要求：
o 入组前行立体定向放射手术或伽玛刀后≥7 天。
o 入组前接受全脑放射治疗后≥14 天。	/DL04 V2
<b>此项下还有以下Q＆A Log中问题，请参照选择。您也可以输入其他问题。谢谢</b>",2022-06-28 22:28:01.734371,1.0,1.0652812176769147e-25,,,1.7038802674499775e-25,2.5023523334654594e-25,1.4562001299235391e-25,cns
